CSIMarket Company Name, Ticker, Customers, else..
 
Mirum Pharmaceuticals Inc   (NASDAQ: MIRM)
 
Price: $100.0750 $-0.83 -0.818%
Day's High: $101.82749938964844 Week Perf: 1.76 %
Day's Low: $ 97.64 30 Day Perf: -0.57 %
Volume (M): 211,499 52 Wk High: $ 127.51
Volume (M$): $ 0 52 Wk Avg: $90.80
Open: $98.49 52 Wk Low: $63.23



 Market Capitalization (Millions $) 6,342
 Shares Outstanding (Millions) 63
 Employees 372
 Revenues (TTM) (Millions $) 618
 Net Income (TTM) (Millions $) -860
 Cash Flow (TTM) (Millions $) 114
 Capital Exp. (TTM) (Millions $) 37

Business Description


Mirum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for patients with rare liver diseases. The company is dedicated to improving the lives of patients by advancing innovative treatments that address unmet medical needs. Mirum Pharmaceuticals is known for its expertise in developing therapies that target rare diseases like Alagille syndrome, progressive familial intrahepatic cholestasis, and bile acid synthesis disorders. The company aims to provide effective and safe treatments for patients suffering from these rare liver diseases, ultimately improving their quality of life.


   Company Address: 989 East Hillsdale Boulevard Foster City 94404 CA
   Company Phone Number: 667-4085   Stock Exchange / Ticker: NASDAQ MIRM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        1.4% 
MRK        0.66% 
OGN        0.11% 
TEVA   -0.36%    
VRTX   -2.5%    
VTRS        1.15% 
• View Complete Report
   



Business Update

LIVMARLI Receives European Commission Approval for Progressive Familial Intrahepatic Cholestasis (PFIC) Treatment

Published Tue, Jul 9 2024 7:16 AM UTC

In an exciting development for patients suffering from progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals, Inc. announced that LIVMARLI (Maralixibat), an oral solution, has received market approval from the European Commission. This authorization comes after a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP), whi...
Business Update

Mirum Pharmaceuticals Triumphs in Europe with LIVMARLI Approval for PFIC, Achieves Significant Revenue Growth...

Published Mon, Jul 8 2024 9:47 PM UTC

Mirum Pharmaceuticals Achieves Milestone with Significant Revenue Growth Foster City, California Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has announced that the European Commission has granted marketing authorization for LIVMARLI (Maralixibat) oral solution. This approval marks a significant development for the treatment of progressive familial intrahepatic cholestasis (PF...
Business Update

Mirum Pharmaceuticals Shines at EASL Congress with Long-Term LIVMARLI Success: A 154% Revenue Surge...

Published Fri, Jun 7 2024 3:42 AM UTC

Mirum Pharmaceuticals: Long-Term LIVMARLI Data Highlights Positive Outcomes at EASL Congress in Milan Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) recently unveiled significant findings at the Annual Congress of the European Association for the Study of the Liver (EASL) in Milan, which took place from June 5 to June 8, 2024. The new data focused on the long-term efficacy of L...
Business Update

Mirum Pharmaceuticals LIVMARLI Receives Positive CHMP Opinion, Poise...

Published Sat, Jun 1 2024 7:27 AM UTC

Mirum Pharmaceuticals Receives Positive CHMP Opinion for LIVMARLI (Maralixibat) Oral Solution in Treating Progressive Familial Intrahepatic Cholestasis in Patients as Young as Three Months Foster City, California, USA A Landmark Achievement in Pediatric HepatologyMirum Pharmaceuticals, Inc., listed on NASDAQ under the ticker MIRM, has announced a significant milestone for...
Business Update

LIVMARLI (Maralixibat) Receives Positive CHMP Opinion for Progressive Familial Intrahep...

Published Fri, May 31 2024 7:38 PM UTC

Recent advancements in the field of pharmaceutical sciences have led to numerous breakthroughs in the treatment of various medical conditions. In this regard, Mirum Pharmaceuticals, a leading pharmaceutical company, has recently received positive news from the Committee for Medicinal Products for Human Use (CHMP) concerning their oral solution, LIVMARLI (maralixibat). The CH...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 10.26
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.7
Working Capital Ratio 7.59
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -14.55 $
Revenues (TTM) 9.75 $
Cash Flow (TTM) 1.81 $
Cash 23.56 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,661,470
Net Income per Employee (TTM) -2,312,384
Receivable Turnover Ratio (TTM) 4.86
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.54

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -24.14 %
Net Margin (MRQ) -38.14 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Mirum Pharmaceuticals Inc's Segments
Livmarli    137.61 % of total Revenue
Bile Acid Medicines    53.11 % of total Revenue
Product    190.72 % of total Revenue
Reportable    190.72 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.